CARLSBAD, Calif., May 10, 2023
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today
announced that management will conduct its 2023 virtual Annual
Meeting of Stockholders followed by a general corporate update on
Thursday, June 1, 2023.
The agenda for the event is as follows:
- 5:00 p.m. – 5:15 p.m. ET (2:00
p.m. – 2:15 p.m. PT) – Virtual
Annual Meeting of Stockholders
-
- All stockholders of record at the close of business on
April 3, 2023, are invited to
participate in the virtual Annual Meeting webcast, which will be
broadcast live at www.virtualshareholdermeeting.com/IONS2023.
- Stockholders of record will receive an official proxy card from
their brokerage firm. Each proxy card contains a 16-digit control
number required to log-in, vote and submit questions during the
webcast.
- Stockholders should contact their brokerage firm before
May 24 for help obtaining a proxy
card or to locate their control number or for instructions to
access the webcast. Ionis does not provide proxy cards or have
access to proxy card information, including 16-digit control
numbers.
- A help line will be available on the registration page of the
live webcast for participants requiring technical assistance in
accessing or participating during the live event. There will not be
a replay of this session.
- 5:30 p.m. ET (2:30 p.m. PT) – Virtual corporate update
-
- Brett P. Monia, Ph.D., Ionis'
chief executive officer, will provide a general corporate update
followed by a question-and-answer session.
- All interested parties may access the webcast live at
https://app.webinar.net/YlW4RyoQrOA. An archived replay of the
webcast will be posted for a limited time following the meeting at
that same address.
- Questions for management may be submitted in advance of the
webcast and will be addressed during the question-and-answer
portion of the webcast. Please submit questions via email to
IonisAnnualMeeting@ionisph.com by May
30th. Questions not addressed during the webcast
will be answered by email following the meeting.
About Ionis Pharmaceuticals
For more than 30 years, Ionis has been a leader in RNA-targeted
therapy, pioneering new markets and changing standards of care.
Ionis currently has four marketed medicines and a promising
late-stage pipeline highlighted by cardiovascular and neurological
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision to
become the leader in genetic medicine, utilizing a multi-platform
approach to discover, develop and deliver life-transforming
therapies.
To learn more about Ionis visit www.ionispharma.com or follow us
on Twitter @ionispharma.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-to-host-2023-virtual-annual-meeting-of-stockholders-301820061.html
SOURCE Ionis Pharmaceuticals, Inc.